The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01172132|
Recruitment Status : Completed
First Posted : July 29, 2010
Last Update Posted : April 18, 2016
The purpose of this study is to determine:
- Condition of intensive care unit (ICU) admission in patients with haematological malignancies.
- ICU hospital and up to one year mortality.
- Assessment of post ICU burden and health related quality at 90-d and 1 year.
|Condition or disease|
- To identify prognostic factors of short and medium term mortality, by underlining the respective weights of organ dysfunction and characteristics of underlined malignancy
- Evaluate the health related quality of life of intensive care survivors(SF36)
- Impact of intensive care on families burden (HADS, IES).
- Assess clinicians' satisfaction ( intensivists, haematologists and intensive care nurses) in relation to medical decision-making.
- Establish the relevance of antifungal treatments.
|Study Type :||Observational|
|Actual Enrollment :||1011 participants|
|Official Title:||Long Term Outcomes in Critically Ill Haematological Patients. The Use of Intensive Care in Critically Ill Cancer Haematological Patients|
|Study Start Date :||November 2009|
|Primary Completion Date :||May 2011|
|Study Completion Date :||November 2011|
- Survival status at one year [ Time Frame: 1 year ]survival status (alive or death) at one year
- Health related quality of life of patients and their relatives [ Time Frame: day 90 and 1 year ]
- ICU mortality [ Time Frame: 1 week (estimated mean time until ICU discharge) ]survival status at ICU discharge
- Survival status [ Time Frame: day 90 ]
- Hospital mortality [ Time Frame: 3 weeks (estimated mean time until Hospital discharge) ]survival status at hospital discharge
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01172132
|Hôpital Saint-Louis, AP-HP|
|Paris, France, 75475|
|Principal Investigator:||Elie Azoulay, MD, PhD||Saint-Louis Hospital, Paris, France|